51 results about "Receptor subunit" patented technology

The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and / or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and / or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

Compositions for reducing dependency and addiction to substances of abuse are provided. Chloride channels such as the GABAA receptors are altered under conditions of dependency and withdrawal such that the electrophysiological properties of the GABAA receptor containing neurons are altered thereby providing a pathophysiological condition resulting in symptoms of dependency and withdrawal such as anxiety. Specifically, under conditions of withdrawal the relative ratio of the a1 receptor subunit decreases relative to the a4 receptor subunit. Endogenous neurosteroid production is also associated with the molecular changes underlying the alterations of GABA-gated chloride channels. Compositions of at least two compounds including at least one inhibitor of neurosteroid production are useful for treating the pathophysiology of addiction, dependency and substance abuse withdrawal.

The invention discloses an IL-2 derivative. At least one cysteine residue is introduced on the basis of wild type IL-2, the binding plane of the IL-2 derivative and an alpha receptor subunit is partially or completely blocked, and meanwhile, the affinity to a beta and gamma receptor subunit compound is basically reserved. The invention also discloses the compound. The compound comprises: the IL-2derivative, wherein a third cysteine residue is introduced into the IL-2 derivative on the basis of wild type IL-2; and a blocking module, wherein a fourth cysteine residue is arranged on or introduced to the blocking module. The third cysteine residue on the IL-2 derivative and the fourth cysteine residue on the blocking module form an intermolecular disulfide bond in order to form the IL-2 derivative and blocking module compound, so the binding plane of the IL-2 derivative and the alpha receptor subunit is partially blocked or completely blocked, and the affinity to the beta and gamma receptor subunit compound is substantially retained.

The invention discloses a RNA aptamer of a targeting hepatocyte and a nucleotide sequence thereof, and relates to the field of hepatic disease diagnosis and treatment. The RNA aptamer provides a novel specific and efficient molecule of a targeting hepatocyte for the field of hepatic disease diagnosis and treatment. In the invention, through using the new combinatorial chemical technology SELEX, and taking hepatic ASGPR (asialoglycoprotein receptor) large subunits as target proteins, an RNA aptamer which can specify the ASGPR is screened from a single-stranded RNA random library. The aptamer can be formed into a special stemloop structure in a random sequence region thereof, combines with big liver ASGP receptor subunit H1 protein with high specific affinity and can combine to liver cells in a targeted mode by high specific affinity. The RNA aptamer provides a new choice for developing a liver disease targeted diagnostic reagent and treatment drug.

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

The invention relates to the identification of a new mouse gene and its trancript that encode a new NR3B subunit of NMDA receptors.

This invention relates to cation conducting GABAA receptors, mutated GABAA receptor subunits, polynucleotide sequences encoding mutated subunits, expression vectors comprising the mutated subunits, host cells capable of expressing the mutated subunits, drug screening methods, and chemical substances identified by the drug screening methods of the invention.

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene. The modified T cell receptor alpha gene comprises an exogenous sequence of interest inserted into an intron within the T cell receptor alpha gene that is positioned 5′ upstream of TRAC exon 1. The exogenous sequence of interest can comprise an exogenous splice acceptor site and / or a poly A signal, which disrupts expression of the T cell receptor alpha subunit. The sequence of interest can also include a coding sequence for a polypeptide, such as a chimeric antigen receptor. Additionally, the endogenous splice donor site and the endogenous splice acceptor site flanking the intron are unmodified and / or remain functional. The invention further provides compositions and methods for producing the genetically-modified cell, and populations of the cell, and methods for the treatment of a disease, such as cancer, using such cells.

Inhibitors of AMPA-type glutamate ion channels are useful as biochemical probes for structure-function studies and as drug candidates for a number of neurological disorders and diseases. Disclosed herein is the identification of an RNA inhibitor or aptamer by an in vitro evolution approach and characterization of its mechanism of inhibition on the sites of interaction by equilibrium binding and on the receptor channel-opening rate by a laser-pulse photolysis technique. The aptamer of the invention is a noncompetitive inhibitor of AMPA-type glutamate ion channels, one that selectively inhibits the GluA2Qflip AMPA receptor subunit without any effect on other AMPA receptor subunits or on kainate or NMDA receptors. Furthermore, the aptamer preferentially inhibits the closed-channel state of GluA2Qflip with a KI=1.5 μM or by ˜15-fold over the open-channel state. The potency and selectivity of this aptamer rival those of small molecule inhibitors. Together, these properties make the aptamers of the present invention promising water-soluble, highly potent, GluA2 subunit-selective drugs.

Peptidyl IL-2Rα ligands and compounds comprising the IL-2Rα ligands are disclosed. The IL-2Rα ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2Rα ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.